VBI Vaccines Inc. got US Food and Drug Administration approval for its hepatitis B vaccine PreHevbrio at possibly an ideal time, with a new recommendation for universal vaccination against the virus for all US adults. With analysts projecting that the annual market for HBV vaccines could reach $500m under the new CDC guidance, VBI said on 1 December that it plans to launch PreHevbrio in the first quarter of 2022 at pricing competitive with the current market leader, GlaxoSmithKline plc’s Engerix-B.
VBI Poised To Take On GSK, Dynavax As Hep B Vaccination Market Takes Off
VBI Vaccines obtained FDA approval of its three-antigen hepatitis B vaccine PreHevbrio and will take on GSK’s Engerix-B and Dynavax’s Heplisav-B as CDC recommends universal HBV immunization.

More from New Products
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.